Affordability

Drug makers sometimes offer copay coupons to lower consumers’ out-of-pocket costs for their brand-name prescriptions, though how private health plans treat those coupons can substantially limit their value to consumers. This issue brief provides an overview of such copay adjustment programs, stakeholder arguments for and against their use, their prevalence, and federal and state efforts to address them.

KFF’s 2024 Women’s Health Survey finds that women aren’t fully aware that the Affordable Care Act (ACA) requires insurance plans to cover the full cost of recommended preventive health care services – especially contraception.

In his latest column, KFF President and CEO Drew Altman provides an early post-mortem on the role health played in the election, discussing the many ways it did play a role in the campaign — even if not a decisive one.

This analysis examines the competitiveness of markets for hospital care based on the share of metropolitan areas controlled by a small number of independent hospitals or health systems and other measures. It finds that nearly half of metropolitan areas across the country had only one or two hospitals or health systems providing general inpatient hospital care in 2022.

Nearly half (47%) of metropolitan areas across the country had only one or two hospitals or health systems providing general inpatient hospital care in 2022, a new KFF analysis finds.The analysis examines the extent of competition among hospitals amid a wave of hospital consolidation that has drawn the attention of…

Oral contraceptives are the most commonly used method of reversible contraception in the U.S. In July 2023, the FDA approved Opill, the first daily oral contraceptive pill to become available over the counter (OTC) without a doctor’s prescription. This issue brief provides an overview of OTC oral contraceptives and laws and policies related to insurance coverage.

This interactive tool, updated with 2022 data, helps users understand health care costs vary by family size, income, insurance, and health status. Use the dropdown menus to explore scenarios and trends in household health spending.

More than two in five (42%) or 57.4 million adults under 65 with private insurance could be eligible under clinical criteria for GLP-1 drugs used to treat people with type 2 diabetes, obesity, or excess weight and weight-related health issues, according to a new KFF analysis. Though only about 3%…

With Vice President Harris promising to address medical debt as part of her economic plan, KFF Executive Vice President for Health Policy Larry Levitt explores why it is a symptom of the broader problem of affordable health care and reviews recent efforts to address it in this JAMA Health Forum post.